je.st
news
Tag: merck
Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ID Week 2016
2016-10-26 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will provide more than 30 scientific data presentations on the companys established and investigational infectious disease medicines and vaccines at ID Week 2016 in New Orleans from Oct. 26-30. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-295-0928Skip Irvine, 215-652-6059orInvestors:Amy Klug, 908-740-1898Michael DeCarbo, 908-740-1807 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
week
commitment
highlights
Kelly Coulson Joins Merck Animal Health’s Food Animal Marketing Team
2016-10-26 02:00:00| ThePigSite - Industry News
US - Merck Animal Health is pleased to announce that Kelly Coulson has joined the company as Swine Marketing Manager, U.S. Food Animal Marketing.
Tags: team
food
marketing
animal
Merck Announces Third-Quarter 2016 Financial Results
2016-10-25 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Third-Quarter 2016 Worldwide Sales Were $10.5 Billion, an Increase of 5 Percent, Including a 1 Percent Negative Impact from Foreign Exchange Third-Quarter 2016 GAAP EPS Was $0.78; Third-Quarter Non-GAAP EPS Was $1.07 Company Updates EPS Guidance: Full-Year 2016 GAAP EPS to be Between $2.02 and $2.09; Full-Year 2016 Non-GAAP EPS to be Between $3.71 and $3.78 Advanced KEYTRUDA Development Program FDA Approved KEYTRUDA for Previously Untreated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) New Data Were Included in Labeling for KEYTRUDA Showing Improved Survival Compared to Chemotherapy in Previously Treated Patients with NSCLC Whose Tumors Express PD-L1 (TPS of 1 Percent or More) FDA Approved KEYTRUDA to Treat Previously Treated Recurrent or Metastatic Head and Neck Cancer KEYNOTE-045 Study Evaluating KEYTRUDA in Previously Treated Advanced Bladder Cancer (Urothelial Cancer) Met Primary Endpoint of Overall Survival and Stopped Early KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2016. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Coulson joins Merck Animal Healths Food Animal Marketing team
2016-10-25 06:00:00| National Hog Farmer
Merck Animal Health is pleased to announce that Kelly Coulson has joined the company as swine marketing manager in U.S. Food Animal Marketing. With nearly two decades of sales and retail experience and 15 years of diverse livestock production knowledge, Coulson brings an extensive background in solution selling, husbandry training and customer service. read more
Tags: team
food
marketing
animal
Merck Animal Health to Acquire Brazilian Animal Health Company Valle
2016-10-21 02:00:00| ThePigSite - Industry News
US - Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has executed an agreement to acquire a controlling interest in Vallée S.A., a leading privately-held producer of animal health products in Brazil.
Tags: company
health
animal
acquire
Sites : [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] next »